STP02 3725

Drug Profile

STP02 3725

Alternative Names: STP02-3725

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ST Pharm
  • Class Anticoagulants; Bile acids and salts; Heparins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Thrombosis

Most Recent Events

  • 31 Dec 2015 Preclinical trials in Atrial fibrillation in South Korea (PO)
  • 31 Dec 2015 Preclinical trials in Deep vein thrombosis in South Korea (PO)
  • 31 Dec 2015 Preclinical trials in Pulmonary embolism in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top